Technology platforms

LFB is an innovative player in recombinant medicinal products, developing, manufacturing and marketing proteins and monoclonal antibodies. LFB’s capacity for innovation in biological medicinal products is demonstrated by two proprietary technology platforms.

KEY FACTS

1ST

The Group’s recombinant antithrombin is the first medicinal product to be produced by rPRO™ technology and registered in Europe and the USA

2

Recombinant medicinal products under clinical development

3

Monoclonal antibodies from the EMABling® platform under clinical development

1ST

The Group’s recombinant antithrombin is the first medicinal product to be produced by rPRO™ technology and registered in Europe and the USA

2

Recombinant medicinal products under clinical development

3

Monoclonal antibodies from the EMABling® platform under clinical development